Article
Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation.
Bone marrow transplantation - 1 Jul 2023
Kong Jun, Zheng Feng-Mei, Wang Zhi-Dong, Zhang Yuan-Yuan, Cheng Yi-Fei, Fu Hai-Xia, Lv Meng, Chen Huan, Xu Lan-Ping, Zhang Xiao-Hui, Huang Xiao-Jun, Wang Yu
Abstract excerpt
In patients with t(8;21) acute myeloid leukemia (AML) with recurrent measurable residual disease (MRD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), pre-emptive interferon-α therapy and donor lymphocyte infusion are noneffective in 30%-50% of patients. Avapritinib is a novel tyrosine kinase inhibitor targeting KIT mutations. We retrospectively report about 20 patients with t(8;21) AML and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.